Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Denali Therapeutics Inc. Director's Dealing 2018

Jun 26, 2018

31637_dirs_2018-06-26_4846e9e5-7a90-4458-9d92-bfe01a64800a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2018-06-22

Reporting Person: Schuth Alexander O. (COO and Secretary)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-06-22 Common Stock M 5918 $5.28 Acquired 5918 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-06-22 Stock Option (right to buy) $5.28 M 5918 Disposed 2027-03-07 Common Stock (5918) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 685089 Indirect

Footnotes

F1: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee.

F2: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.